Enhancing Access: Cross-Sector Collaboration in Healthcare

By HEOR Staff Writer

November 20, 2023

The Medicine Accessibility Challenge

High-income countries are increasingly struggling to afford medicines. New and established drugs are often too expensive and scarce. Gene and cell therapies, cancer pharmaceuticals, and orphan drugs are expensive and burden individuals and health systems.

Broken Pharma Systems

Pharmaceutical system fragmentation, especially in Europe, limits equal medicine availability. The outpatient and hospital sectors frequently have separate public bodies for medicine reimbursement and procurement. This distinction can cause differences in inpatient and outpatient medicine, which can have serious cost consequences, especially when hospitals start expensive therapy. The goal of a recent study was to determine whether cross-sectorial pharmaceutical policies improve medicine access in Europe.

Policymakers and Stakeholders

Policymakers and stakeholders are crucial to pharmaceutical reimbursement and procurement cross-sectorial collaboration. The roles include starting and assessing the collaboration. Policymakers can enable cross-sector collaboration with legal and regulatory frameworks. They can also start change and harmonise policy across industries. These policies can be developed and implemented using the skills and understanding of stakeholders. They can also promote collaboration benefits to stakeholders and the public. To be effective, these jobs require a productive atmosphere with trust, transparency, and stakeholder understanding.

Limitations and Future Plans for Cross-Sector Collaboration in Healthcare

The review focused on Europe, thus its findings may not apply to other regions. The evaluation did not examine cross-sector collaboration barriers, which would affect policy creation and implementation. Similar research in other regions and investigations of cross-sector collaboration barriers should solve these limitations. Longitudinal research are needed to assess how these agreements affect medicine access. This would strengthen evidence that cross-sector coordination improves access to inexpensive medicines.

Reference url

Recent Posts

CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...
New Federal Actions to Combat Misleading Prescription Drug Ads in 2025

By João L. Carapinha

September 11, 2025

Misleading prescription drug ads have become a pressing concern in the United States, prompting decisive federal action. What are the new measures targeting deceptive pharmaceutical advertising, and how will these changes affect public health and healthcare costs? In September 2025, a